Mitochondrial DNA Acts as a “First Hit” for Antibody-Mediated TRALI
Transfusion-related acute lung injury (TRALI) continues to be the primary cause of death associated with blood transfusions, despite ongoing efforts to understand its complex development. Medical experts have long recognized that TRALI occurs through a two-stage process requiring both an initial vulnerability factor and a subsequent trigger.
In the majority of TRALI cases approximately 80%, the triggering event involves immune antibodies, specifically those targeting HLA molecules or neutrophil antigens present in transfused blood. The remaining cases have been linked to biological fat molecules, cellular particles, and substances that accumulate during blood storage. However, identifying what makes patients vulnerable in the first place has proven challenging.
Researchers observed that intensive care patients, who face elevated TRALI risk, frequently show increased levels of mitochondrial genetic material circulating outside their cells. To explore this connection, scientists conducted experiments using laboratory mice. They administered purified mitochondrial components or mitochondrial DNA, subsequently introducing antibodies to simulate transfusion conditions.
The outcomes were striking: mice experienced substantial lung damage characterized by fluid retention in lung tissue, elevated inflammatory chemical messengers including MIP-2 (equivalent to human IL-8), white blood cell accumulation in lungs, reduced body temperature, and severe respiratory compromise all significantly worse than control subjects.
A breakthrough came when researchers blocked TLR-9, a cellular receptor that detects mitochondrial DNA. This intervention markedly decreased symptom severity, indicating that mitochondrial DNA and TLR-9 together initiate the vulnerability phase of TRALI.
These findings open possibilities for preventive therapies targeting either mitochondrial DNA or TLR-9 receptors, though clinical validation requires further investigation.
References:
